Real life behaviour of direct oral anticoagulants in patients with nonvalvular atrial fibrillation and morbid obesity
Open Access
- 11 November 2021
- journal article
- research article
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 37, 100913
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060European Heart Journal, 2013
- 2013 ACCF/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes and Coronary Artery DiseaseCirculation, 2013
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Anticoagulating obese patients in the modern eraBritish Journal of Haematology, 2011
- Thromboxane Production in Morbidly Obese SubjectsThe American Journal of Cardiology, 2011
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Population Pharmacokinetic Analysis of the New Oral Thrombin Inhibitor Dabigatran Etexilate (BIBR 1048) in Patients Undergoing Primary Elective Total Hip Replacement SurgeryThe Journal of Clinical Pharmacology, 2007
- Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy SubjectsThe Journal of Clinical Pharmacology, 2007
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005